Competing interests
MP, Neuromyelitis optica Study
EYE DISEASES
JI reports no conflicts of interest and funding by the Bundesinstitut für Risikobewertung (BfR), LM received honoraria from Biogen and Merck, as well as research funding from the Deutsche Multiple Sklerose Gesellschaft, MP received honoraria for lecturing from Argenx, Alexion, Novartis, Bayer Health Care, Sanofi-Aventis, Biogen and Merck; SS received no financial compensation or support from any organization or entity that may have an interest in the content of this manuscript; MW declares nor conflict of interest and nor funding received for the preparation of this report; OA has received, with approval of the Heinrich Heine University, advisor fees, honoraria, or travel reimbursements from Alexion, Almirall, Biogen, Horizon, MedImmune, Merck, Novartis, Roche, and Teva; research support from the German Science Foundation (DFG), the German Ministry of Education and Research (BMBF), Biogen, and Novartis. He is member of the European Reference Network—Eye Diseases (ERN-EYE) consortium and member of the German Neuromyelitis optica Study Group (NEMOS); SGM received honoraria for lecturing and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS, and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Bundesinstitut für Risikobewertung (BfR), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, Gemeinsamer Bundesausschuss (G-BA), German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and by Alexion, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva; PA received research grants from BMS, Celgene, German Research Association, EFRE NRW, Ipsen, Merck, Merz, Novartis and speaker honoraria, travel support and recompensation for serving on advisory boards from Allergan, Abbvie, BMS, Celgene, Ipsen, Hexal, Janssen Cilag, Lilly, Merck, Merz, Novartis, Sanofi, TEVA.